UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 700 shares, a decrease of 90.0% from the February 29th total of 7,000 shares. Based on an average daily volume of 14,300 shares, the short-interest ratio is currently 0.0 days.

UCB Stock Performance

OTCMKTS UCBJY traded up $0.05 on Friday, hitting $61.62. 4,504 shares of the company’s stock were exchanged, compared to its average volume of 11,564. The firm’s 50-day moving average price is $53.47 and its two-hundred day moving average price is $45.18. UCB has a fifty-two week low of $34.85 and a fifty-two week high of $62.53.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.